Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE

Share this content:
Childhood cancer survivors face a much greater risk of VTE in the first 5 years after diagnosis, researchers found.
Childhood cancer survivors face a much greater risk of VTE in the first 5 years after diagnosis, researchers found.

Childhood cancer survivors face a 25-fold increased risk of venous thromboembolism (VTE) in the first 5 years after diagnosis compared with the general population. According to a study published in the Journal of Clinical Oncology, this increased risk continues throughout their lifespan.

This was the first study to look at the long-term risk of VTE in cancer survivors. The study included 24,355 childhood cancer survivors, and 5051 siblings who participated in the Childhood Cancer Survivor Study (CCSS), a multi-institutional cohort. Participants' diagnoses were made between 1970 and 1999, had a median age at last follow-up of 28.7 years, and a median follow-up since diagnosis age of 21.3 years.

The incidence of late VTE among survivors and siblings was 1.1 and 0.5 events per 1000 years, respectively, with 2.5 excess events per 100 survivors over 35 years. The cumulative incidence of VTE at 35 years post diagnosis was 4.9% for survivors and 2.4% for siblings. Survivors with the highest risk of late VTE were female survivors who were obese or underweight. Osteosarcoma survivors treated with limb-sparing approaches, survivors exposed to cisplatin, and survivors who developed active cancer were also at higher risk. VTE diagnosis was also associated with an increased mortality risk.

“Providers should be aware of the incidence of VTE among cancer survivors,” wrote the authors, who encouraged the development of interventions, particularly for obese patients, and those treated with cisplatin and limb-sparing approaches.

Reference

Madenci AL, Weil BR, Liu Q, et al. Long-term risk of venous thromboembolism in survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2018;36(31):3144-3150.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs